BRAIN announces €60m round of financing to expand its buy-and-build strategy
The supervisory board and the board of management of the biotechnology company BRAIN AG agreed on a €60m capital increase during a meeting of the supervisory board held on 19 November 2012. The capital increase helps pave the way for the implementation of BRAIN’s “buy-and-build” industrialisation strategy. A smaller share of the funds flow will serve to further advance BRAIN’S technology platforms, which play a crucial role in the NatLifE 2020 and ZeroCarb FP innovation alliances funded by the German Ministry of Education and Research (BMBF).
The largest ever round of financing in the area of white biotechnology is led by BRAIN shareholders MP Beteiligungs-GmbH (Family Office PUTSCH) based in Kaiserslautern, Germany, and MIG Fonds, one of the largest institutional investors in the area of biotechnology, and involves several other investors.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.